← Leaderboards
Charles Daniel Meyers
Tempero Bio, Inc.
$5,310,920
Attributed
$5,310,920
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.3M · FY2022–23$5M$3.8M$2.5M$1.3M$0
'22
'23
Funding mix
By agency
NIH$5,310,920 · 1
By mechanism
U01$5,310,920 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Abstinence”
- Ian Gurrell · Astrazeneca Pharmaceuticals, Lp$5,256,914
- Mark Sorenson · Nirsum Laboratories, Inc.$4,866,388
- Glenn Short III · Atai Therapeutics, Inc.$2,923,842
- Georgette Suidan · Cerevel Therapeutics, Llc$2,700,000
- Omar El-Shahawy · New York University School Of Medicine$2,623,868
- Lorraine I Kelley-Quon · Children'S Hospital Of Los Angeles$2,495,528
Research focus
AbstinenceAddictive BehaviorAddictionAlcohol ConsumptionAlcoholsAlcohol Seeking BehaviorAlcohol Use DisorderAffectAntagonistAttenuatedBehaviorClinical EfficacyClinically SignificantClinical ResearchCocaineCocaine DependenceCocaine ExposureAnimal EfficacyCocaine Self-AdministrationCocaine UseCocaine Use DisorderCocaine UsersCravingCues
Grant awards (2)
TMP-301, A Negative Allosteric Modulator of type 5 metabotropic glutamate receptors (mGluR5), for Treatment of Cocaine Use Disorder$3,250,400
U01 · FY2023 · DA · contact PI
TMP-301, A Negative Allosteric Modulator of type 5 metabotropic glutamate receptors (mGluR5), for Treatment of Cocaine Use Disorder$2,060,520
U01 · FY2022 · DA · contact PI